Summary: Tumors arising from the pancreatic endocrine (islet) cells represent a heterogeneous group of lesions. Some tumors present with well characterized syndromes, while others appear to be nonfunctioning. Eighteen patients with pancreatic endocrine tumors who received surgical treatment at Kurume University Hospital during a 24-year period were reviewed. There were 10 patients with nonfunctioning tumors including 3 patients with benign tumors, and 8 patients with insulinomas. No patients had multiple endocrine neoplasms. Location of the pancreatic tumor was determined preoperatively in 83.3% of the patients. Immunohistochemical analysis of the resected specimens showed multi immunoreactivity to gut hormones among benign lesions and one malignant lesion, whereas malignant lesions showed no or mono imm noreactivity except in one case. In this series, there were no characteristic immunohistochemical findings in the tumors. Both patients with malignant and benign lesions have good prognoses if the main tumors and metastatic lesions are removed.
INTRODUCTION
The recognition of various clinical syndromes, the development of radio immunoassay (RIA) for humoral substances, and the improvement of techniques for preoperative identification and location of tumors have contributed to improved diagnosis and care of patients with pancreatic endocrine tumors.
In this article, we present the clinical features, methods of diagnosis, immunohistological characteristics and outcomes after surgical treatment for a consecutive series of 18 patients with pancreatic endocrine tumors during the past 24 years.
MATERIALS AND METHODS
Since 1974, the primary surgical experience at our Preoperative diagnosis of location of the endocrine tumors was made in 16 patients by abdominal computed tomography (CT), ultrasonography (US), and selective angiography. Diagnosis of the tumor location was difficult in only two patients, but by intraoperative US and the palpation of the pancreas, it was possible to identify these tumors at the pancreas body. size ranged from 10 mm to 35 mm in patients with a benign tumor, and the tumor sizes in 10 of the 11 patients were under 20 mm (Table 2) . In patients with benign tumors, findings by various diagnostic modalities are shown in Table 3 . The findings in 7 of the 11 patients showed low echoic masses by US, 7 of 10 patients showed tumor stains by angiography, and 6 of 10 patients showed mass lesions by CT. In the 8 patients with an insulinoma, the results of PTPS revealed the step-up of IRI level with hypoglycemia attacks (Table 3 ).
In patients with malignant tumors, all diagnostic modalities revealed abnormal findings of pancreatic vessel encasement by angiography, and occlusion or stenosis of the pancreatic duct by endoscopic retrograde pancreatography (Table 4) .
The results of preoperative examination of plasma concentrations of gut hormones in 10 patients are shown in Table 5 . Only two patients showed high serum glucagon level,. but they showed no signs or symptoms resulting from hypersecretion of glucagon. Insulinomas and benign tumors of the pancreas are sometimes visible on the pancreatic surface, but if the tumors are not palpable, we routinely use intraoperative US to help identify the tumors, exclude the presence of multi centric disease, and to delineate the relevant anatomy, especially to identify the relation of the tumors to the pancreatic duct.
Most of the tumors can be resected or enucleated because of their compact nature. Six of 11 patients with benign tumors underwent partial resection of the pancreas and 5 patients underwent distal pancreatectomy.
Seven patients with malignant tumors underwent resection of the primary tumor because of the presence of liver and lymph nodes metastases.
Pancreatoduodenectomy
was performed in 4 patients, and distal pancreatectomy in 3.
Immunohistochemical study of resected endocrine tumors was performed in 15 patients. All of the patients with a benign tumor showed some type of hormonal reaction by immunohistochemical study. Multi-hormonal reactions for pancreatic polypeptide (PP), insulin, somatostatin, glucagon, or gastrin were observed in 8 of 15 resected specimens by immunohistochemical examination. Only two patients showed no hormonal reaction, and 3 of 6 patients with malignant tumors revealed hormonal reactions by immunohistochemical stains of the resected spec-imens (Table 6 ). It is notable that nonfunctioning tumors apparently have a delayed diagnosis as evidenced by their large size at presentation. They did not produce clinically recognizable syndromes, but were accompanied by abdominal and back pain, weight loss, nausea and vomiting, or abdominal mass. According to Mao et al. [5] , the association of pancreatitis with neuroendocrine tumors of the pancreas is uncommon, whereas its association with exocrine pancreatic cancer is well recognized. Preoperative diagnosis of the location of endocrine tumors was a problem, because the tumors tend to be small (C2 cm), particularly for insulinomas. The accuracy of angiography in this series ranged from 70% for benign endocrine tumors to 100% for the larger, malignant tumors. CT and US can also be useful, and PTPS was an especially useful diagnostic tool for Insulinomas to detect small lesions which could not be found by US, CT, or angiography.
Although the clinical presentation of nonfunctioning endocrine tumors is similar to that of a pancreatic adenocarcinoma, the prognoses are extremely different. Whereas a pancreatic adenocarcinoma is usually fatal within 6 months after the diagnosis, long-term survival is common in patients with nonfunctioning endocrine carcinomas. All of our patients, except for the 2 most recent patients, have survived more than 7 years since their diagnoses. In fact, one patient lived for 21 years after the initial operation and she also lived for 7 years after occurrence of severe para-aortic lymph nodes metastases (patient No malignant-l , in Table 2 ) [6] . Two patients found to have liver metastases at the initial operation have also followed a good course without any signs of recurrence.
As metastases from endocrine carcinomas are confined to the upper abdominal lymph nodes and liver, curative resection may be possible in these patients. For this reason, non-curative debulking of metastatic tumors may improve survival.
Many authors [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] reported long-term survival in patients who had been treated by tumor resection or by palliative treatment such as cholecysto-or choledocho-jejunostomy. Distal pancreatectomy is preferred for lesions in the body and tail of the pancreas. Enucleation is preferred for small, benign lesions of the pancreas. Large and malignant lesions in the head of the pancreas require pancreatoduodenectomy.
According to Moertel et al.
[17], hepatic arterial occlusion can frequently produce major regression of endocrine tumors with relief from the hormonal syndromes for patients with hepatic-dominant metastases of endocrine carcinomas. Sequential chemotherapy may improve the rate and duration of the regression. At worst, pancreatic endocrine tumors are slow growing cancers, therefore, the characteristics of these tumors justify a surgical approach if possible [18] [19] [20] . On 
